Modeling Glanzmann thrombasthenia using patient specific iPSCs and restoring platelet aggregation function by CD41...

Area of Science:

• Hematology
• Stem Cell Biology
• Genetic Disorders

Background:

• Glanzmann thrombasthenia (GT) is a rare monogenic hemorrhagic disorder characterized by defective platelet aggregation.
• The condition arises from mutations in genes encoding platelet glycoproteins, primarily ITGA2B.

Purpose of the Study:

• To generate patient-specific induced pluripotent stem cells (iPSCs) from a Glanzmann thrombasthenia patient.
• To differentiate these iPSCs into functional platelets and assess their aggregation capabilities.
• To evaluate the potential of stem cell-based gene therapy for GT.

Main Methods:

• Fibroblasts from a GT patient with ITGA2B mutations were reprogrammed into iPSCs.
• GT-iPSCs were differentiated into platelets (GT-iPS-platelets).
• Flow cytometry and in vitro platelet aggregation assays were performed. Wild-type ITGA2B gene was introduced to assess functional restoration.

Main Results:

• Successfully generated GT-iPSCs and differentiated them into GT-iPS-platelets.
• GT-iPS-platelets exhibited characteristic markers (CD41-/CD42b+/CD61-) and failed to activate PAC-1.
• In vitro aggregation assays confirmed defective platelet aggregation in GT-iPS-platelets.
• Restoration of wild-type ITGA2B expression normalized CD41 expression and platelet aggregation.

Conclusions:

• Patient-derived iPSCs can be differentiated into platelets with GT-specific defects.
• Exogenous expression of ITGA2B can correct the platelet aggregation defect.
• Patient-specific iPSCs represent a promising platform for developing stem cell-based gene therapy for Glanzmann thrombasthenia.